GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

Nucala's approval offers hope for uncontrolled COPD. This new drug reduces flare-ups, a key benefit for Black Americans.

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

FDA approves Nucala as add-on therapy for COPD with high eosinophils, offering new hope by reducing flare-ups in patients unresponsive to inhaled treatments.

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth indication. The drug is now cleared to treat certain patients with chronic ...

The U.S. Food and Drug Administration has approved Nucala as a supplementary treatment for elderly individuals with severe chronic obstructive pulmonary disease .Nucala is the only approved biologic, ...

Get Instant Summarized Text (Gist) The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults with inadequately controlled COPD and a blood eosinophil count ≥150 ...

Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate ...

reinforced the efficacy of Nucala (mepolizumab) in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, irrespective of whether they ...

FRIDAY, May 23, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled ...